GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iBio Inc (AMEX:IBIO) » Definitions » Operating Margin %

iBio (IBIO) Operating Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is iBio Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. iBio's Operating Income for the three months ended in Mar. 2024 was $-3.63 Mil. iBio's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, iBio's Operating Margin % for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for iBio's Operating Margin % or its related term are showing as below:

IBIO' s Operating Margin % Range Over the Past 10 Years
Min: -36380   Med: -1312.15   Max: -360.13
Current: -36380


IBIO's Operating Margin % is ranked worse than
95.7% of 1023 companies
in the Biotechnology industry
Industry Median: -155.93 vs IBIO: -36380.00

iBio's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

iBio's Operating Income for the three months ended in Mar. 2024 was $-3.63 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-18.19 Mil.


iBio Operating Margin % Historical Data

The historical data trend for iBio's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iBio Operating Margin % Chart

iBio Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -782.36 -854.88 -1,312.15 -1,576.27 -

iBio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -10,206.00 - -

Competitive Comparison of iBio's Operating Margin %

For the Biotechnology subindustry, iBio's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iBio's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, iBio's Operating Margin % distribution charts can be found below:

* The bar in red indicates where iBio's Operating Margin % falls into.



iBio Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

iBio's Operating Margin % for the fiscal year that ended in Jun. 2023 is calculated as

Operating Margin %=Operating Income (A: Jun. 2023 ) / Revenue (A: Jun. 2023 )
=-29.343 / 0
= %

iBio's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-3.626 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iBio  (AMEX:IBIO) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


iBio Operating Margin % Related Terms

Thank you for viewing the detailed overview of iBio's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


iBio (IBIO) Business Description

Traded in Other Exchanges
N/A
Address
8800 HSC Parkway, Bryan, TX, USA, 77807-1107
iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates. Its products are used to combat various areas such as fibrotic diseases, cancers, and infectious diseases. The company operates in two segments: Biopharmaceuticals and Bioprocessing activities, conducted within iBio, Inc. and CDMO segment, conducted within iBio CDMO.
Executives
Martin Brenner officer: Chief Scientific Officer C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Felipe Duran officer: Interim CFO 8800 HSC PARKWAY, BRYAN TX 77807
William D Clark director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Evert B. Schimmelpennink director C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Isett Thomas Francis 3rd director, officer: CEO and Executive Chairman C/O IBIO INC. 600 MADISON AVENUE, SUITE 1601, NEW YORK NY 10022
Robert Matthew Lutz officer: See Remarks 900 NORTHBROOK DRIVE, SUITE 200, TREVOSE PA 19053
Randy Joe Maddux officer: Chief Operating Officer 2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Alexandra Kropotova director RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807
Gary Sender director C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVE, NEW YORK NY 10020
Linda Washington Armstrong director 8800 HSC PARKWAY, BRYAN TX 77807
John Delta officer: Principal Accounting Officer 8800 HSC PARKWAY, BRYAN TX 77807
Eastern Capital Ltd 10 percent owner 10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Robert L Erwin officer: President C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
James P. Mullaney officer: Chief Financial Officer C/O IBIO, INC., 600 MADISON AVE., SUITE 1601, NEW YORK NY 10022
Carl Desantis 10 percent owner C/O CDS INTERNATIONAL HOLDINGS, 3299 NW SECOND AVE, BOCA RATON FL 33431